Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
• Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6• Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory.
WAYNE, Pa., Feb. 10, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that.
Paddy should be limited to 65 lakh acres only in a year, experts tell CM
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
It is a pleasure to report that the Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is up 31% in the last quarter. But that...
SEATTLE--(BUSINESS WIRE)--Comcast Washington today announced a $55,000 contribution to Asian Counseling and Referral Service (ACRS) in support of the non-profit organization’s COVID-19 response effort and digital literacy training needs in Western Washington.…
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced the appointment of Vincent Milano to its board of directors, effective January 7, 2020. Vincent Milano has served as the President and Chief Executive Officer, and as a member of the board of directors, of Idera Pharmaceuticals, Inc., a publicly held biopharmaceutical company, since December 2014. Prior to joining Idera, between 1996 and 2014, Mr. Milano served in increasingly senior roles at ViroPharma Inc., a pharmaceutical company that was acquired by Shire Plc in 2014, most recently as Chairman, President and Chief Executive Officer from 2008 to 2014.
Q4 2019 Aclaris Therapeutics Inc Earnings Call
WAYNE, Pa., May 26, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that.
PEG earnings call for the period ending March 31, 2020.
Projected Cash Runway into the First Quarter of 2022Borrowed $11 Million from Term Loan Facility WAYNE, Pa., May 07, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a.
If our analysis is correct, we may see a fairly strong trend reversal over the next 5+ trading days as this pattern/setup complete and confirm.
Aclaris (ACRS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WAYNE, Pa., Feb. 19, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it.
Is Aclaris Therapeutics, Inc. (NASDAQ:ACRS) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 InhibitorProjected Cash Runway into the Third Quarter.
COVID-19 has created new challenges for lung cancer screening programs, in many cases, delaying screenings by several months and creating more difficulty for administrative and scheduling teams.
Aclaris Therapeutics, Inc. (CICN), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (“SVB”) pursuant to which Aclaris has borrowed $11.0 million. Aclaris believes the proceeds from the loan, in combination with its existing cash, cash equivalents, and marketable securities, will be sufficient to fund its operations into the first quarter of 2022. The term loan requires interest only payments beginning April 1, 2020 and continuing through March 1, 2022, followed by monthly installments of principal, plus monthly payments of accrued interest, starting on April 1, 2022 and continuing through March 1, 2024.
In 2012 Neal Walker was appointed CEO of Aclaris Therapeutics, Inc. (NASDAQ:ACRS). This analysis aims first to...
As of late, it has definitely been a great time to be an investor Aclaris Therapeutics
The funds will extend the 'cash runway' for a company that six months ago shifted its product development focus.
Already at high risk for infection, older AAPI people are also more likely to live in poverty, and many are socially and linguistically isolated.
Anyone researching Aclaris Therapeutics, Inc. (NASDAQ:ACRS) might want to consider the historical volatility of the...
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.